Y-mAbs Therapeutics, Inc. is a pivotal player in the biopharmaceutical industry, dedicated to advancing antibody-based therapeutics aimed at addressing unmet needs in cancer treatment. Headquartered in New York, the company is at the forefront of innovative therapies, with a focus on developing and commercializing novel treatments that target specific cancer antigens. With a robust pipeline and strategic commercial initiatives, Y-mAbs is positioned to impact patient outcomes significantly while creating value for investors in the burgeoning oncology market.